Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1950 1
1951 2
1952 1
1953 1
1954 1
1955 5
1956 1
1957 1
1958 1
1959 1
1960 1
1961 5
1962 2
1964 2
1966 1
1971 1
1983 1
1984 1
1993 1
1995 1
1996 1
1998 2
2000 2
2003 2
2005 2
2007 1
2008 2
2009 3
2010 2
2011 1
2012 1
2013 3
2014 1
2015 2
2016 6
2017 8
2018 4
2019 3
2020 7
2021 13
2022 12
2023 18
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Results by year

Filters applied: . Clear all
Page 1
FIGO staging of endometrial cancer: 2023.
Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, Lindemann K, Mutch D, Concin N; Endometrial Cancer Staging Subcommittee, FIGO Women's Cancer Committee. Berek JS, et al. Among authors: lindemann k. Int J Gynaecol Obstet. 2023 Aug;162(2):383-394. doi: 10.1002/ijgo.14923. Epub 2023 Jun 20. Int J Gynaecol Obstet. 2023. PMID: 37337978 Free article.
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA; RUBY Investigators. Mirza MR, et al. N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Epub 2023 Mar 27. N Engl J Med. 2023. PMID: 36972026 Clinical Trial.
FIGO staging of endometrial cancer: 2023.
Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, Lindemann K, Mutch D, Concin N; Endometrial Cancer Staging Subcommittee, FIGO Women's Cancer Committee. Berek JS, et al. Among authors: lindemann k. J Gynecol Oncol. 2023 Sep;34(5):e85. doi: 10.3802/jgo.2023.34.e85. Epub 2023 Aug 8. J Gynecol Oncol. 2023. PMID: 37593813 Free PMC article.
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marmé F, Lindemann K, Colombo N, Mądry R, Glasspool R, Vergote I, Korach J, Lheureux S, Dubot C, Oaknin A, Zamagni C, Heitz F, Gladieff L, Rubio-Pérez MJ, Scollo P, Blakeley C, Shaw B, Ray-Coquard I, Redondo A; OReO/ENGOT-ov38 investigators. Pujade-Lauraine E, et al. Among authors: lindemann k. Ann Oncol. 2023 Dec;34(12):1152-1164. doi: 10.1016/j.annonc.2023.09.3110. Epub 2023 Oct 4. Ann Oncol. 2023. PMID: 37797734 Free article. Clinical Trial.
Top 10 priorities for future infertility research: an international consensus development study.
Duffy JMN, Adamson GD, Benson E, Bhattacharya S, Bhattacharya S, Bofill M, Brian K, Collura B, Curtis C, Evers JLH, Farquharson RG, Fincham A, Franik S, Giudice LC, Glanville E, Hickey M, Horne AW, Hull ML, Johnson NP, Jordan V, Khalaf Y, Knijnenburg JML, Legro RS, Lensen S, MacKenzie J, Mavrelos D, Mol BW, Morbeck DE, Nagels H, Ng EHY, Niederberger C, Otter AS, Puscasiu L, Rautakallio-Hokkanen S, Sadler L, Sarris I, Showell M, Stewart J, Strandell A, Strawbridge C, Vail A, van Wely M, Vercoe M, Vuong NL, Wang AY, Wang R, Wilkinson J, Wong K, Wong TY, Farquhar CM; Priority Setting Partnership for Infertility. Duffy JMN, et al. Fertil Steril. 2021 Jan;115(1):180-190. doi: 10.1016/j.fertnstert.2020.11.014. Epub 2020 Nov 30. Fertil Steril. 2021. PMID: 33272617 Free article.
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Sukhin V, Cloven N, Pereira de Santana Gomes AJ, Contreras Mejía F, Reiss A, Ayhan A, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Lazzari R, Chang CL, Lampé R, Zhu H, Oaknin A, Christiaens M, Polterauer S, Usami T, Li K, Yamada K, Toker S, Keefe SM, Pignata S, Duska LR; ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators. Lorusso D, et al. Among authors: lindemann k. Lancet. 2024 Apr 6;403(10434):1341-1350. doi: 10.1016/S0140-6736(24)00317-9. Epub 2024 Mar 20. Lancet. 2024. PMID: 38521086 Clinical Trial.
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Oaknin A, Gladieff L, Martínez-García J, Villacampa G, Takekuma M, De Giorgi U, Lindemann K, Woelber L, Colombo N, Duska L, Leary A, Godoy-Ortiz A, Nishio S, Angelergues A, Rubio MJ, Fariñas-Madrid L, Yamaguchi S, Lorusso D, Ray-Coquard I, Manso L, Joly F, Alarcón J, Follana P, Romero I, Lebreton C, Pérez-Fidalgo JA, Yunokawa M, Dahlstrand H, D'Hondt V, Randall LM; ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030 Investigators. Oaknin A, et al. Among authors: lindemann k. Lancet. 2024 Jan 6;403(10421):31-43. doi: 10.1016/S0140-6736(23)02405-4. Epub 2023 Dec 1. Lancet. 2024. PMID: 38048793 Clinical Trial.
A national precision cancer medicine implementation initiative for Norway.
Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES; CONNECT Public–Private Partnership Consortium; Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R; InPreD-Norway and National Molecular Tumor Board Consortium; IMPRESS-Norway Consortium; Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å. Taskén K, et al. Nat Med. 2022 May;28(5):885-887. doi: 10.1038/s41591-022-01777-4. Nat Med. 2022. PMID: 35513529 No abstract available.
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.
Corbaux P, You B, Glasspool RM, Yanaihara N, Tinker AV, Lindemann K, Ray-Coquard IL, Mirza MR, Subtil F, Colomban O, Péron J, Karamouza E, McNeish I, Kelly C, Kagimura T, Welch S, Lewsley LA, Paoletti X, Cook A. Corbaux P, et al. Among authors: lindemann k. Eur J Cancer. 2023 Sep;191:112966. doi: 10.1016/j.ejca.2023.112966. Epub 2023 Jul 4. Eur J Cancer. 2023. PMID: 37542936 Free article.
Response: FIGO staging of endometrial cancer 2023.
Concin N, Matias-Guiu X, Fotopoulou C, Creutzberg C, Mutch D, Gaffney D, Lindemann K, Kehoe S, Berek JS; FIGO Committee on Women's Cancer. Concin N, et al. Among authors: lindemann k. Int J Gynaecol Obstet. 2024 Jan;164(1):369-372. doi: 10.1002/ijgo.15277. Epub 2023 Dec 6. Int J Gynaecol Obstet. 2024. PMID: 38055215 No abstract available.
126 results